Epidermal Delivery of Ani-Aging Ingredients

NCT ID: NCT01847066

Last Updated: 2013-05-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2013-09-30

Brief Summary

To assess the safety and efficacy of an ablative fractional, 2940-nm laser combined with the US Impact and cosmetic -formulations for improving the appearance of wrinkles, acne scars and pigmented skin.

Detailed Description

This is a randomized, split face & dorsal hand side by side study. The purpose of the side by side study is to determine whether the use of the Impact with the ablative fractional 2940nm laser and cosmetics improves the cosmetic outcomes when compared to using just the ablative fractional 2940nm laser with the cosmetics.

This is a non-significant risk aesthetic clinical study. Only cosmetic formulations will be used during the study, These cosmetic formulations do not contain any ingredient categorized as a drug by the FDA.

Conditions

Wrinkles; Acne Scars; Pigmentation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Erbium plus cosmetics plus Impact

Erbium 2940 plus cosmetics plus Impact Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.

Group Type: ACTIVE_COMPARATOR

Erbium 2940 plus cosmetics plus Impact

Intervention Type: DEVICE

Laser used in all arms

Erbium 2940 plus cosmetics

Erbium 2940 plus cosmetics Patient shall be treated with erbium 2940nm laser, cosmetics

Group Type: ACTIVE_COMPARATOR

Erbium 2940 plus cosmetics

Intervention Type: DEVICE

laser

Erbium 2940 plus cosmetics plus Impact

Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.

Group Type: ACTIVE_COMPARATOR

Erbium 2940 plus cosmetics plus Impact

Intervention Type: DEVICE

Laser used in all arms

Erbium 2940nm plus cosmetics

Patients shall be treated with Erbium 2940nm laser plus cosmetics only.

Group Type: ACTIVE_COMPARATOR

Erbium 2940 plus cosmetics

Intervention Type: DEVICE

laser

Interventions

Erbium 2940 plus cosmetics plus Impact

Laser used in all arms

Intervention Type: DEVICE

Erbium 2940 plus cosmetics

laser

Intervention Type: DEVICE

Other Intervention Names

Laser; Laser

Eligibility Criteria

Inclusion Criteria

• Male or female in good general health between 35 to 65 years of age.
• Must be willing to execute informed consent. Patient must also consent to having photos taken at each visit.
• A potential subject must exhibit:

Facial wrinkling, acne scars or pigmentation.

• For FEMALE PATIENTS OF CHILDBEARING POTENTIAL, must have had a regular menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation) and is willing to use an acceptable form of birth control during the entire course of the study [i.e., acceptable methods of birth control are oral contraceptives, contraceptive patches/rings/implants Norplanit®, Depo-Provena®, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of partner with a documented second acceptable method of birth control should the subject become sexually active]. All systemic birth control measures must be in consistent use at least 30 days prior to study participation.
• Must be willing to comply with study visits and complete the entire course of the study.

Exclusion Criteria

Subjects meeting any of the following criteria will be excluded from participation:

• A subject that underwent a laser / light treatment on the face within 12 months, or any topical treatment on the face with 6 months.
• A subject with any UNCONTROLLED systemic disease. A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study.
• A subject with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
• A subject using any topical product containing a retinoid, retinol, or other vitamin A derivative within 3 months prior to or during the study period.
• A subject using any systemic steroid therapy within 6 months prior to or during the study period.
• A subject that has been treated with Botox/Dysport or filler/biostimulatory molecule injections to his/her face within the past six months.
• A subject using any topical medicated creams, lotions, powders, etc. on the treatment areas during the study period, other than the study treatment regimen within 14 days.
• A subject that has previously been treated with systemic retinoids within the past year (e.g., Accutane®, Roche Dermatologics).
• A subject with recently excessive facial exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing). During the study, when excessive sun exposure is unavoidable, subjects must wear appropriate protective clothing (e.g. hat) and comply with the study dosing regimen of daily application of the dispersed sunblock.
• A subject with a recent history or active presence of any facial skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e. moderate to severe acne vulgaris, atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, excessive facial hair or coloration).
• A female subject who is pregnant, nursing an infant or planning a pregnancy during the study [throughout the course of the study, women of child-bearing potential must use reliable forms of contraception (i.e., oral contraceptive, intrauterine device, abstinence, or spermicides and condoms used in combination)].
• Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
• Subjects who are pregnant, breast-feeding, or planning a pregnancy. Females of childbearing potential, must be either:
• using the same form (i.e. brand) and dosage regimen of an oral contraceptive pill or of a hormonal implant continuously for three months prior to study entry and continue during the entire study, or
• willing to use a different form of birth control during the study other than any form of hormonal methods such as oral contraceptive pills and hormonal implants 30 day prior to study entry and during the entire study period. For the purpose of this study, the following are considered acceptable methods of birth control: double-barrier methods (e.g.: condoms and spermicide), abstinence and vasectomies of partner with a documented second acceptable method of birth control should the subject become sexually active.

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Alma Lasers Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

NY Derm LLC

New York, New York, United States

Countries

United States

Other Identifiers

ALMA 013-001

Identifier Type: -

Identifier Source: org_study_id